Rating Change
Cantor Fitzgerald analysts reiterated a Overweight rating on AbbVie Inc. (NYSE:ABBV) on July 06, 2026.
Rating Change Cantor Fitzgerald analysts reiterated a Overweight rating on AbbVie Inc. (NYSE:ABBV) on July 06, 2026. Market Context AbbVie Inc.

Cantor Fitzgerald analysts reiterated a Overweight rating on AbbVie Inc. (NYSE:ABBV) on July 06, 2026.
AbbVie Inc. operates in the Healthcare sector. The stock currently trades at $254.76 with a market capitalization of $410.1B. The stock has gained 17.5% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AbbVie Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 06, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jun 23, 2026 | Piper Sandler | Overweight | N/A |
| Jun 23, 2026 | Canaccord Genuity | Buy | N/A |
| May 15, 2026 | Evercore ISI Group | Outperform | N/A |
| May 14, 2026 | Piper Sandler | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View ABBV Stock Page
A Overweight rating from Cantor Fitzgerald reflects the analyst's outlook on AbbVie Inc. (NYSE:ABBV). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ABBV forecast page.
Current market data
NYSE · ABBV
$265.12
Down: -$1.88 · -0.71%
Live quote updated
Keep reading